MR antagonists such as eplerenone and spironolactone have been used for the treatment of various forms of heart failure and hypertension for decades, and eplerenone is now shown to slow the progression of heart disease in DMD (Raman et al, 2015, 2017). Here, NR3C2 is linked to hypertensive disorder.